EGFR and lung cancer: Our previous study reported that the EGFR tyrosine kinase inhibitors gefitinib and erlotinib activate autophagy in human lung cancer cells.[22] Induction of autophagy in response to these TKIs could be cytoprotective or cytodestructive, which contributes to the anticancer efficacy of these drugs as well as to drug resistance.